Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy
This economic evaluation examines the cost-effectiveness of low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B goals for lipid-lowering therapy in a cohort of 250 000 atherosclerotic cardiovascular disease–free and statin-eligible US adults.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.